A phase II study of linsitinib (OSI-906) in patients with asymptomatic or mildly symptomatic (non-opioid requiring) metastatic castrate resistant prostate cancer (CRPC).
Jorge A. Garcia
Consultant or Advisory Role - Astellas Pharma
Paul Elson
No relevant relationships to disclose
Matthew M. Cooney
No relevant relationships to disclose
Allison Janine Tyler
No relevant relationships to disclose
Victoria Rezash
No relevant relationships to disclose
Ernest C. Borden
No relevant relationships to disclose
Robert Dreicer
No relevant relationships to disclose